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Abstract This study evaluated the eﬀect of physiologi-
cal L-thyroxine (L-T4) treatment on bone metabolism
in patients with subclinical hypothyroidism. Sixty-six
women with subclinical hypothyroidism (TSH
11.7 ± 0.8 mIU/l) were randomly assigned to receive
L-T4 or placebo for 48 weeks. Sixty-one of 66 patients
completed the study. Individual L-T4 replacement
(mean dosage 85.5 ± 4.3 lg/day) was performed tar-
geting euthyroid thyroid-stimulating hormone (TSH)
levels. The primary outcome measure was 24- and 48-
week change in markers of bone formation (total and
bone alkaline phosphatase [ALP, bone ALP], osteo-
calcin [OC]) and resorption (pyridinoline [PYD] and
deoxypyridinoline [DPD], C-terminal cross-linking
telopeptide type I [CTX]). Secondary outcomes were
48-week changes in bone mineral density (BMD) of the
lumbar spine and hip, measured by dual-energy X-ray
absorptiometry. Compared with placebo, L-thyroxine
(n=31) resulted in signiﬁcant activation of bone
turnover. Overall, a signiﬁcant treatment eﬀect was
observed for DPD (between-group diﬀerence 16.0%;
95%CI, 10.9 to 21.1), CTX (29.9%; 95%CI, 23.3 to
36.5), and bone ALP (13.2%; 95%CI, 6.6 to 19.7)
after 24 weeks. At the end of the study, lumbar BMD
in the both treatment groups diﬀered by 1.3%
(95%CI, )2.9 to 0.5) with lower levels in L-thyroxine
treated women. Signiﬁcant diﬀerence in BMD between
groups was also observed at the trochanter. We con-
clude that physiological L-thyroxine treatment acceler-
ates bone turnover reﬂecting early activation of bone
remodeling units in the initial replacement of subclin-
ical hypothyroidism. The observed bone loss could be
interpreted as an adaptive mechanism on decreased
bone turnover in preexistent hypothyroidism, and not
as L-thyroxine-induced clinically important bone loss.
However, long-term studies are needed to conﬁrm this
assumption.
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Introduction
The relation between thyroid hormone and bone in overt
hyperthyroidism is well established. Hyperthyroidism
accelerates bone turnover and shortens the normal bone
remodeling cycle, leading to osteoporosis and increased
fracture risk. Thyroid hormones are among the most
commonly used medications and, according to observa-
tional studies, the use of thyroid hormones to suppress
pituitary TSH in the treatment of thyroid cancer, goiters,
or thyroid nodules seems to have an adverse eﬀect on bone
homeostasis, especially in postmenopausal women [1].
While bone remodeling is accelerated in hyperthy-
roidism, it has been demonstrated that the remodeling
cycle in overt hypothyroidism is increased to almost
2 years with an increase in mineralized cortical bone [2].
Based on a histomorphometric study, patients with
untreated hypothyroidism have a higher mean cortical
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bone width, which in turn, decreases during thyroxine
treatment [3]. Some cross-sectional and longitudinal
studies [4, 5, 6, 7, 8, 9, 10], but not all [11, 12, 13, 14, 15,
16], evaluating bone mineral density in patients with
overt hypothyroidism have suggested that thyroid hor-
mone replacement could have a deleterious eﬀect on
bone mineral density.
Subclinical hypothyroidism (SCH) has been de-
tected with increasing frequency in recent years with
an estimated prevalence of about 5% to 16% in the
female population. This syndrome is characterized by
elevated thyroid-stimulating hormone (TSH) levels in
the presence of normal circulating thyroid hormones,
thyroxine (T4) and triiodothyronine (T3) [17]. Though
it has been shown that thyroid hormone replacement
may be beneﬁcial in patients with SCH, less is known
about its potential role on bone remodeling. Only a
few studies have evaluated the eﬀect of thyroxine
replacement on bone in patients with mild thyroid
failure [18, 19, 20, 21]. We therefore initiated a double-
blind, placebo- and TSH-controlled study with the aim
to investigate the eﬀect of physiological L-thyroxine
treatment on bone remodeling in patients with sub-
clinical hypothyroidism.
Subjects and methods
Study population
The present study was part of a prospective, double-blind, placebo-
controlled trial whose design and patient characteristics have been
described previously [22]. Brieﬂy, between September 1993 and
May 1997, 66 women with SCH were enrolled in the study. All
patients were examined and followed up in the Thyroid Research
Unit of the Division of Endocrinology at the University Hospital,
Basel, Switzerland. The inclusion criteria were as follows: age 18–
75 years; TSH level >5.0 mIU/l on two consecutive blood tests;
exaggerated TSH response >35 mIU/l after TRH stimulation; free
T4 concentration within the normal range; good general health as
assessed by a full medical and endocrine work-up. The exclusion
criteria were as follows: pituitary/hypothalamic disorders or other
nonthyroidal illnesses; thyroid hormone medication up to
12 months prior to enrollment. Forty-nine of 66 patients had a
postmenopausal hormone status with identical ratios between both
treatment groups (L-T4: 25/33, and placebo: 24/33). In patients
treated with estrogen-replacement therapy (nine in each group) the
dose remained unchanged over the whole study period.
The study was terminated early in two participants due to
previously unknown serious comorbidities (endometrial cancer,
malignant astrocytoma; both assigned L-T4) and in another patient
due to rapid progression to clinically overt hypothyroidism
(assigned placebo). Two patients on antiresorptive osteoporosis
treatment (alendronate, pamidronate) were excluded for further
analysis. Apart above speciﬁed estrogen replacement therapy in
postmenopausal women, none of the patients was on drugs known
to aﬀect bone metabolism (i.e., glucocorticoids, statins, calcitonin,
anticonvulsants, and vitamin D or analogues).
A total of 61 women were analyzed. The underlying thyroid
disorders leading to SCH consisted of autoimmune thyroiditis
(n=32),Graves’ disease (n=22, treatedwith radioiodine, surgery, or
with carbimazole), toxic multinodular goiter (n=2; treated with
radioiodine), and surgically resected goiter (n=5). The median time
after radioactive iodine therapy before entry into the study was
11.0 years (range 1–42 years). The frequencies of underlying thyroid
disorders were equally distributed in the L-T4 and placebo group.
Design and organization of the study
Eligible patients were sequentially assigned either to the L-T4
treatment group (n=33) or to the placebo group (n=33) according
to a predeﬁned randomization list. The study duration for each
patient was 50 weeks, including a 2-week run-in phase before
starting treatment. During the ﬁrst 24 weeks, the L-T4 dosage was
adapted continuously every 6 weeks in order to achieve an optimal
physiological hormone replacement with euthyroid TSH levels (i.e.,
basal TSH concentration within the reference range [0.1–4.0 mIU/
l]). L-Thyroxine (Henning Berlin; Berlin, Germany) was given in the
fasting state. The dosage was controlled every 6 weeks to ascertain
an optimal replacement regimen (mean L-T4 dosage at the end of
the study: 85.5 ± 4.3 lg daily, range 50–125 lg). To guarantee
blinding, patients in the placebo group received identical-appearing
tablets with dosage adjustments in concordance to their randomly
assigned patients in the treatment group. The local Ethics Com-
mittee for Human Studies approved the study. Written informed
consent was obtained from all study participants.
Laboratory measurements
Measurements of hormones and biochemical markers of bone
turnover were assessed at the baseline visit, after 24 weeks, and at
the end of the study after 48 weeks. Serum and urine samples were
collected in the fasting state between 0800 and 1000 hours, imme-
diately put on ice and processed within 30 min. Thereafter, they
were stored at )70C until measurement. Serum TSH concentra-
tion (reference range 0.1 to 4.0 mIU/l) was measured by a sensitive
immunometric assay (Delﬁa; Wallac, Turku, Finland). Free T4 (8.0
to 23.0 pmol/l) and total T3 (1.2 to 3.1 nmol/l) were determined by
microparticle enzyme immunoassays IMx (Abbott, Baar, Switzer-
land). Serum estradiol (follicular phase, 90 to 716 pmol/l; post-
menopausal, 37 to 145 pmol/l) were measured by an ECL
immunoassay (Elecsys; Roche Diagnostics, Basel, Switzerland).
Total alkaline phosphatase (ALP) activity was measured according
to the IFCC guidelines, using an automated colorimetric assay and
para-nitrophenyl phosphate as a substrate at 37C (reference range
31 to 108 U/l; Hitachi System 704 analyzer; Roche Diagnostics,
Basel, Switzerland). Bone alkaline phosphatase (bone ALP; refer-
ence range 8.0 to 16.6 lg/l; Tandem-MP Ostase; Beckman Coulter,
Fullerton, USA) and serum osteocalcin (OC; reference range 7.7 to
32.0 ng/ml; ELSA-Osteo; CisBio International, France) were
determined by an immunometric assay. Urine pyridinium collagen
cross-links (pyridinoline and deoxypyridinoline) were measured by
high performance liquid chromatography (HPLC) (Crosslinks;
BioRad, Munich, Germany), and the results were expressed in
relation to the urinary creatinine. The detection limit for both of
the collagen cross-links was 5.0 pmol/l, with a reference range of 60
to 100 pmol/mmol for pyridinoline/creatinine and 9 to 20 pmol/
mmol for deoxypyridinoline/creatinine. Serum C-terminal
telopeptides of type I collagen (CTX; reference range 0.13 to
4.1 lg/l) was measured on the Elecsys 2010 automated analyzer
(Beta-crosslaps; Roche Diagnostic, Rotkreuz, Switzerland) using
the b-crosslaps/serum reagents [23]. The intra- and interassay var-
iation for the various assays used were OC, 5.3% and 6.2%; ALP,
3.2% and 4.8%; bone ALP, 6.7% and 8.1%; pyridinium cross-
links, 4% and 10%; CTX, 3.4% and 4.6%; respectively. Urinary
calcium and creatinine were assayed using an autoanalyzer
(Hitachi, Roche Diagnostics, Rotkreuz, Switzerland). The calcium
results were expressed in relation to the urinary creatinine, the
reference range being 0.1 to 0.32 mmol/mmol.
Bone density measurements
Bone mineral density at the lumbar spine and hip (femoral neck,
greater trochanter, Ward’s triangle) was evaluated by dual-energy
X-ray absorptiometry (DXA) using a Lunar Expert densitometer
(Lunar, Madison, WI, USA). Lumbar vertebrae with prevalent or
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incident fractures at L1 to L4 or degenerative bone disease were not
included in the bone mineral density measurements. To assess the
short-term precision of the system in this population, a single re-
peat measurement in 20 patients was performed [24]. In each case,
the patient was removed from the scanner and repositioned
between measurements. The coeﬃcient of variation of individual
measurements was 1.1% for the spine, 1.8% for the femoral neck,
1.7% for Ward’s triangle, and 2.1% for the trochanteric region.
Statistical methods
All data are expressed as means ± standard errors of the mean
(SEM). Unpaired t-test (two-sided), or Mann-Whitney U-test in the
case of nonparametric distributions, were used to identify demo-
graphic variables showing diﬀerences among the groups. Diﬀer-
ences of frequencies were tested with the v-square test or Fisher
exact test, as appropriate. To compare study variables during study
periods, one-way ANOVA for repeated measures with post hoc
comparisons corrected for multiple testing by least squares diﬀer-
ence (LSD) was used. Signiﬁcance was deﬁned as p<0.05. Data
were analyzed using Statistica for Windows (version 6.0; StatSoft,
Tulsa, OK, USA).
Results
Baseline characteristics
Table 1 summarizes the baseline characteristics of the 66
study participants. Sixty-one women (mean age
57.1 ± 1.3 years) completed the study as foreseen by the
study protocol and were included in the analysis. The
two groups of women with SCH (L-thyroxine, n=33;
placebo, n=33), as well as the 61 women in the ﬁnal
analysis (L-thyroxine, n=31; placebo, n=30), were well
matched for age, body mass index, smoking habits,
estrogen status, and dietary calcium intake (using stan-
dardized questionnaires). The patient groups were also
similar with respect to thyroid hormone concentrations,
biochemical markers of bone turnover, and bone min-
eral density. Basal TSH levels were mildly to markedly
elevated (range 4.7–46.3 mIU/l) with exaggerated TSH
response >35 mIU/l after TRH in both treatment
groups; peripheral thyroid hormone concentrations (fT4,
T3) were within the lower reference range. According to
the WHO deﬁnition, the number of patients with lumbar
osteoporosis (T-score <)2.5: L-T4, n=3, and placebo,
n=2) and lumbar osteopenia (T-score )1 to )2.5: L-T4,
n=15, and placebo, n=10) were comparable in both
treatment groups (p=ns). Similar proportions were
documented for femoral BMD values (T-score <)2.5:
L-T4, n=0, and placebo, n=1; T-score )1 to )2.5:
L-T4, n=10, and placebo, n=11; p=ns for both com-
parisons).
Eﬀect of treatment on thyroid hormone concentrations
To decrease the TSH concentration to the euthyroid
reference range, the L-T4 dosage was adapted at 6-week
intervals (mean dosage 85.5 ± 4.3 lg daily). In all
L-T4-treated patients, TSH levels remained in the
euthyroid range for at least the last 24 weeks. Mean
serum TSH level at the end of the study was
3.1 ± 0.3 mIU/l. No patient had a blunted or absent
TSH response to thyrotropin-releasing hormone.
Peripheral thyroid hormone concentrations increased
(fT4) and decreased (T3) signiﬁcantly within the refer-
ence range. No change in any variable of thyroid
function could be seen in the placebo group (Table 2).
Eﬀect of treatment on biochemical markers
of bone turnover
In all women, serum biochemical markers of bone for-
mation and resorption were measured at baseline, after
24 weeks, and at the end of the study after 48 weeks.
Signiﬁcant changes of bone markers could be seen in
L-T4-treated patients only, whereas placebo-treated
patients showed no signiﬁcant increases during the study
period (Table 2).
Bone formation markers
The mean baseline total alkaline phosphatase (ALP)
level for the entire sample (n=61) was within the female
reference range. During L-T4 treatment, ALP levels
Table 1 Baseline data of the study population (n=66). Character-
istics at baseline were not signiﬁcantly diﬀerent in either treatment
group (analysis was done by intention-to-treat: signiﬁcance was
determined by unpaired t-test (two-sided) or by Mann-Whitney
U-test in nonparametric distribution, and v-square test or Fisher
exact test, as appropriate). Data are mean ± SEM
Characteristics L-T4 group
(n=33)
Placebo group
(n=33)
Age (years) 57.1±1.8 57.1±1.9
Body mass index (kg/m2) 25.6±0.7 26.4±0.7
Smokers (%) 5 (15.1%) 2 (6.1%)
Pre-/postmenopausal 8/25 9/24
Years since menopause 11.6±1.6 11.8±1.4
Estradiol (pmol/l) 334.6±86.7 296.7±52.4
Dietary calcium intake (mg/day) 915.7±71.8 756.7±73.4
TSH (mIU/l) 14.4±1.7 11.3±1.0
fT4 (pmol/l) 11.9±0.3 12.2±0.3
T3 (nmol/l) 2.0±0.1 1.9±0.1
Calcium (mmol/l) 2.3±0.0 2.3±0.0
Phosphate (mmol/l) 1.1±0.0 1.1±0.0
Total alkaline phosphate (U/l) 63.3±3.6 69.8±4.8
Bone-speciﬁc alkaline
phophatase (U/l)
9.6±0.7 10.2±0.8
Osteocalcin (ng/ml) 24.3±1.7 23.3±1.6
C-terminal telopeptide
type I collagen (lg/l)
0.4±0.0 0.4±0.0
U-pyridinoline/creatinine
(pmol/mmol)
70.3±4.8 68.7±4.3
U-deoxypyridinoline/creatinine
(pmol/mmol)
13.9±1.0 13.7±0.9
U-calcium/creatinine (mmol/mmol) 0.3±0.0 0.3±0.0
BMD, lumbar spine (g/cm2) 1.086±0.032 1.070±0.036
BMD, femoral neck (g/cm2) 0.932±0.022 0.908±0.029
BMD, trochanter (g/cm2) 0.796±0.019 0.759±0.031
BMD, Ward’s triangle (g/cm2) 0.776±0.028 0.750±0.033
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increased progressively after 24 weeks (p=0.05) and
48 weeks (p=0.004). In contrast, no signiﬁcant change
of bone-speciﬁc alkaline phosphatase (bone ALP) levels
could be observed during L-T4 treatment (after
24 weeks, p=0.05). At baseline the mean osteocalcin
(OC) level was normal at 23.6 ± 1.2 ng/ml. As shown,
OC levels increased signiﬁcantly after 24 weeks
(p=0.03) with no further change thereafter in L-T4
treated patients. The mean percentage changes of serum
ALP diﬀered signiﬁcantly between the two treatment
groups after 24 weeks (D13.2; 95%CI, 6.6 to 19.7;
p=0.02). Bone ALP levels were signiﬁcantly changed
after 24 weeks (D7.7%; 95%CI, 2.3 to 13.2; p=0.02)
whereas no diﬀerences could be observed for serum OC
(Fig. 1).
Bone resorption markers
At baseline, mean values for urine pyridinoline (PYD,
69.5 ± 3.4 pmol/mmol) and urine deoxypyridinoline
(DPD, 13.8 ± 0.7 pmol/mmol) for all 61 women were
in the lower part of the reference range for postmeno-
pausal women. During L-T4 treatment, PYD and DPD
levels increased progressively with signiﬁcant changes
after 24 weeks (p=0.003, for both markers) and
48 weeks (p=0.016, and p=0.014). C-Terminal te-
lopeptide type I collagen (CTX) levels were diminished
in the whole cohort (CTX; 0.4 ± 0.02 lg/l) at baseline
with signiﬁcant increase in L-T4 treated women after
24 weeks (p=0.02). A comparison of the mean treat-
ment eﬀects between the two treatment groups (L-T4
and placebo) was signiﬁcant for DPD (D16%; 95%CI,
10.9 to 21.1; p=0.001) and CTX (D29.9%; 95%CI, 23.3
to 36.5; p=0.002) after 24 weeks with no signiﬁcance
thereafter (DPD, p=0.06; CTX, p=0.09) (Fig. 1).
Eﬀect of treatment depending on previous history
of hyperthyroidism
To investigate the impact of the nature of underlying
thyroid disease as confounding variable on bone
metabolism, all study participants were separated based
on their past history of hyperthyroidism. Baseline
characteristics, including thyroid hormones, markers of
bone turnover, and BMD, were not signiﬁcantly diﬀer-
ent in women either with (Graves’ disease and multi-
nodular goiter; n=24) or without a past history of
hyperthyroidism (Hashimoto’s thyroiditis, thyroidec-
tomy for euthyroid goiter; n=37). The change in bone
formation and resorption markers was signiﬁcantly
increased in both L-T4 treatment groups (no hyperthy-
roidism: ALP, PYD, and DPD, p=0.02 / past history of
hyperthyroidism: bone ALP and OC, p=0.03; PYD,
p=0.004; DPD, p=0.006; CTX, p=0.01). Interestingly,
a comparison of the mean treatment eﬀect revealed a
more deleterious eﬀect of thyroid hormone replacement
on DPD (p=0.037) in patients with a past history of
thyrotoxicosis.
Eﬀect of treatment on bone density measurements
In all women, BMD was measured at baseline and at the
end of the study. The mean baseline lumbar BMD for all
Table 2 Parameters before, and after 24 and 48 weeks of treatment
with L-T4 (n=31) or placebo (n=30). To compare study variables
during L-T4 or placebo treatment, ANOVA with repeated mea-
sures was used (analysis was done per protocol). Paired Student’s t-
test (two-sided) or Wilcoxon signed rank test in the case of non-
parametric distributions were applied to evaluate the change in
values after 24 and 48 weeks in comparison to baseline within
groups. Data are mean ± SEM
Parameters Treatment with L-T4 (n=31) Treatment with placebo (n=30) Between-group
comparison
(ANOVA)Before
treatment
After
24 weeks
After
48 weeks
Before
treatment
After
24 weeks
After
48 weeks
TSH (mIU/l) 12.8±1.4 3.6±0.5d 3.1±0.3d 10.8±1.0 10.2±0.7 9.9±0.6 p<0.0001
fT4 (pmol/l) 11.6±0.3 16.9±0.5
d 17.8±0.8d 12.0±0.3 12.4±0.4 12.3±0.4 p<0.0001
T3 (nmol/l) 2.0±0.1 1.7±0.1
b 1.7±0.1d 1.9±0.1 1.8±0.1 1.9±0.1 p=0.002
Calcium (mmol/l) 2.3±0.0 2.3±0.0 2.3±0.0 2.3±0.0 2.3±0.0 2.3±0.0 p=0.812
Phosphate (mmol/l) 1.1±0.0 1.1±0.0 1.1±0.0 1.1±0.0 1.1±0.0 1.1±0.0 p=0.906
Total alkaline
phosphate (U/l)
63.3±3.7 65.7±3.8a 68.0±4.6c 66.7±3.8 65.2±3.7 64.8±3.5 p=0.047
Bone-speciﬁc
alkaline phosphatase (U/l)
9.6±0.7 10.2±0.8a 10.2±0.8 10.2±0.9 9.2±0.8 9.8±0.9 p=0.147
Osteocalcin (ng/ml) 24.7±1.8 26.2±1.5b 25.2±1.3 22.3±1.7 22.7±1.8 22.7±1.7 p=0.674
C-terminal telopeptide
type I collagen (mg/l)
0.36±0.04 0.41±0.05b 0.39±0.04 0.35±0.03 0.32±0.03b 0.35±0.04 p=0.013
U-pyridinoline/creatinine
(pmol/mmol)
70.7±5.0 77.7±5.0c 81.5±7.1b 68.3±4.7 65.1±5.4 68.9±4.7 p=0.259
U-deoxypyridinoline/creatinine
(pmol/mmol)
14.0±1.0 15.4±1.0c 16.2±1.4b 13.6±0.9 13.0±1.1 13.7±0.9 p=0.237
U-calcium/creatinine
(mmol/mmol)
0.3±0.0 0.3±0.0 0.3±0.0 0.3±0.0 0.3±0.0 0.3±0.0 p=0.812
ap=0.05; bp<0.05; cp<0.005; dp<0.001
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subjects was 1.08 ± 0.02 g/cm2 (range 0.68 to 1.64 g/
cm2). Expressed as a Z-score, the mean bone density was
0.23 ± 1.15 SD (range )2.70 to 3.56 SD) above that
expected for age and gender. The mean BMD of the
femoral neck was 0.92 ± 0.02 g/cm2 (range 0.58 to
1.35 g/cm2) with a Z-score of 0.42 ± 0.13 SD (range
)1.69 to 3.30 SD). During L-T4 treatment, signiﬁcant
decrease of BMD was found at the axial skeleton
()0.014 ± 0.005 g/cm2;)1.2%; p=0.006), while no
changes were observed at the other sites. In contrast,
placebo-treated women showed signiﬁcant increase
of BMD at the trochanter after 48 weeks
(0.026 ± 0.007 g/cm2;4%; p=0.002) and at Ward’s tri-
angle (0.049 ± 0.054 g/cm2; 5.9%; p=0.0003), with a
trend at the femoral neck (1.3%; p=0.07) and no change
at the lumbar spine. A comparison of the mean treat-
ment eﬀect between L-T4 and placebo was signiﬁcant at
the spine (p=0.029), at the trochanter (p=0.026), and at
Ward’s triangle (p=0.015; Table 3).
Discussion
Based on this randomized placebo-controlled study we
demonstrate that bone turnover, assessed by biochemi-
cal markers of bone formation and resorption, is
accelerated during administration of physiological
L-thyroxine doses for the correction of thyroid hormone
deﬁciency in women with SCH as compared to placebo-
treated controls. Nonetheless, during short-term
administration of thyroid hormone replacement the
observed increase in bone turnover is associated with
only minimal loss of bone density which might not be of
clinical relevance in the long term, but can be interpreted
as an adaptive mechanism on decreased bone turnover
in preexistent subclinical hypothyroidism.
SCH has been detected with increasing frequency in
recent years and is characterized by the ﬁnding of ele-
vated TSH levels in the presence of normal circulating
thyroid hormones. Though management and treatment
of SCH is still matter of debate, recent data showing a
beneﬁcial eﬀect of L-thyroxine treatment on clinical and
metabolic parameters argues for replacement therapy in
at least some of the aﬀected patients [17]. However, data
Fig. 1 Eﬀect of L-thyroxine (n=31) and placebo (n=30) on
biochemical markers of bone formation (bone ALP, OC) and
bone resorption (DPD, CTX). Signiﬁcance between the treatment
groups was assessed by Mann-Whitney U-test. The curves show the
mean changes (±SEM) from baseline
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are scarce on the early eﬀects of physiological L-thy-
roxine doses on bone integrity.
The acceleration of bone turnover in SCH is likely
due to the same mechanisms as are known from
replacement therapy in overt hypothyroidism. Bone
remodeling, characterized by osteoclast-stimulated bone
resorption followed by osteoblast-dependent bone rem-
ineralization, takes more than half a year to complete in
euthyroid condition, and is signiﬁcantly prolonged to
almost 2 years in hypothyroidism [2]. The correction of
a hypothyroid state with thyroid hormones may be
associated with an increase in new remodeling units.
Activation of osteoclast resorptive surfaces might
therefore be responsible for transient acceleration of
bone turnover during replacement therapy [25]. Hence,
our ﬁndings of a consistent rise of bone resorption
(DPD, PYD, CTX) and formation markers (ALP, bone
ALP, OC) might represent an incipient and transient
‘‘catch-up’’ of bone remodeling in SCH. This is consis-
tent with a study by Nystro¨m and coworkers who
demonstrated an increase of serum concentrations of
procollagen III peptide, a nonspeciﬁc marker of early
collagen formation, 6 months after the initiation of L-
thyroxine therapy in SCH [18], and with some reports of
increased OC and ALP levels in patients with overt
hypothyroidism [4, 6, 26]. However, bone markers like
OC, ALP, and procollagen I were not altered in other
observational studies during the early treatment of overt
hypothyroidism [10, 16, 27, 28]. Interestingly, in our
study, changes in ALP were more pronounced than
changes in bone ALP. It has been shown that in the
absence of liver disease (which was the case in our
study), serum ALP has a higher diagnostic sensitivity
than bone ALP to detect changes in bone turnover,
while in contrast, bone ALP is more speciﬁc for skeletal
changes than ALP [29]. We found a consistent rise of
bone formation markers after 24 weeks of L-T4
replacement (ALP, p=0.05; bone ALP, p=0.05; OC,
p<0.05). Thereafter only ALP showed a further in-
crease, while bone ALP and OC remained stable. We
assume that the later changes may be detected only by
the more sensitive ALP measurement.
Based on cross-sectional and longitudinal studies,
overtly hypothyroid women who are started on L-thy-
roxine replacement therapy experience a reduction in
both cortical and trabecular bone. During the 1st year
of treatment, a bone mineral loss of 5.4% to 13% at the
lumbar spine [4, 6, 7] and a loss of 5.1% to 7% at the
femoral neck [6, 7] have been described. This reduction
in bone volume has been conﬁrmed in a histomorpho-
metric study using iliac crest biopsies in patients
receiving thyroid hormones for 6 months showing that
in a hypothyroid state, bone loss is predominantly af-
fected at the cortical site [3]. This is due to the fact that
mean cortical bone width is higher than in euthyroid
controls as result of decreased bone remodeling in
hypothyroidism [2]. However, bone loss seems to be only
an adaptive mechanism of newly started thyroid hor-
mone replacement,as in most of the longitudinal studies
over 5 to 20 years no signiﬁcant bone loss was observed
during long-term L-thyroxine replacement compared
with euthyroid controls [11, 14, 15, 16, 27]. Only one
study reported signiﬁcant loss in bone density in pre-
menopausal women with Hashimoto’s thyroiditis during
L-thyroxine replacement for an average of 7.5 years. In
contrast to the signiﬁcant reduction of femoral BMD of
7%, no change in lumbar spine bone density was
observed [8].
In SCH we found signiﬁcant diﬀerences of lumbar
and femoral bone mineral density between L-T4- and
placebo-treated patients after 48 weeks of treatment.
This was mainly due to a consistent increase in bone
mineral density in placebo-treated patients (at the hip)
and a small loss of bone density in L-thyroxine treated
women (at the lumbar spine). Therefore we postulate
that the observed signiﬁcant change in BMD is pre-
dominantly aﬀected by the lower bone turnover in pla-
cebo-treated patients resulting in more mineralized
bone, and not due to increased bone resorption in L-T4-
treated women. Our ﬁndings are in agreement with
earlier studies that observed a trend toward reduced
bone mineral density in L-thyroxine-treated patients
with SCH [19, 20], and in accordance, though to a lesser
degree, with the changes observed in overt hypothy-
roidism. Interestingly, as the increases of biochemical
markers of bone turnover seen were all within the nor-
mal ranges, this was suﬃcient to produce the changes in
BMD seen over 1 year.
Data from the literature indicate that cortical bone
seems to be more susceptible to thyroid hormone–in-
duced bone loss than trabecular bone [1]. The percentage
of trabecular bone diﬀers markedly between anatomical
sites, representing more than 50% for lumbar spine and
femoral trochanter, and about 25% for femoral neck.
Based on the ﬁndings of our study, signiﬁcant decrease
in bone mineral density could be observed only in pre-
dominantly trabecular sites (lumbar spine, p=0.029;
trochanter, p=0.026) and not at cortical sites. This is in
Table 3 Mean percentage changes (95% CI) in bone mineral density from baseline within groups, and comparison between groups.
Signiﬁcance between the treatment groups was assessed by Student’s t-test or Mann-Whitney U-test in nonparametric distribution,
respectively
Site Placebo (n=30) L-Thyroxine (n=31) Between-group comparison (p value)
Lumbar spine 0.05% ()0.8 to 0.8) )1.2% ()2.0 to )0.4) p=0.029
Femoral neck 1.3% ()0.5 to 3.1) 0.1% ()1.5 to 1.7) p=0.312
Trochanter 3.8% (1.4 to 6.2) )0.01% ()2.1 to 2.1) p=0.026
Ward’s triangle 5.9% (2.6 to 9.3) 0.5% ()2.5 to 3.4) p=0.015
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contrast to patients with hyperthyroidism, who have
more bone loss at cortical than trabecular sites.
It remains uncertain whether the observed thyroid
hormone–mediated reductions in bone density in hypo-
thyroidism are associated with an increased fracture
rate. Results from a recent study evaluating the long-
term risk of developing osteoporotic fractures in patients
on long-term L-thyroxine treatment is reassuring, as no
association with hip fractures was detected [30]. How-
ever, as patients have been prospectively followed for
1 year only, a harmful eﬀect of long-term L-T4
replacement on bone turnover and bone mineral density
can not be ruled out by this study. In particular this may
apply to a less controlled clinical setting with the risk of
L-T4 overtreatment.
Our study must be interpreted in the context of its
limitations. The major limitation of our study is the
short-term follow-up without fracture endpoints. Only
larger controlled trial studies will be able to address the
question of whether the observed acceleration in bone
turnover during the 1st year of L-T4 replacement in
patients with SCH results in an increased fracture rate in
the long-term or not. Furthermore, when evaluating the
eﬀect of thyroid hormone replacement on bone integrity,
a few factors known to inﬂuence bone mass have to be
taken into account. As this study was controlled for the
factors such as gender, age of patients, body mass index,
menopausal status and mean age at menopause, intake
of drugs interfering with bone metabolism, and smoking
habits, special focus has to be put on the nature of
underlying thyroid disease. This study is limited by the
fact that patients with SCH were randomized irrespec-
tive of their past history of hyperthyroidism, and one
could argue that the observed treatment eﬀects might be
due to a propensity for increased bone turnover. At
study entry, levels of bone markers and BMD in all
women were comparable, irrespective of their past his-
tory of hyperthyroidism. However, a more deleterious
eﬀect of L-thyroxine in patients with a past history of
hyperthyroidism cannot be ruled out as DPD levels were
signiﬁcantly more altered in these patients.
In conclusion, we demonstrate by this double-blind,
placebo-controlled study that physiological, TSH-gui-
ded L-thyroxine treatment accelerates bone turnover in
the initial treatment of SCH accompanied by clinically
nonsigniﬁcant loss of trabecular bone. This may reﬂect
early re-activation of decreased bone remodeling caused
by SCH, and not thyroid hormone–induced clinically
important bone loss. However, long-term studies are
needed to conﬁrm this assumption.
References
1. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret
GY (1996) Eﬀects on bone mass of long term treatment with
thyroid hormones: a meta-analysis. J Clin Endocrinol Metab
81:4278–4289
2. Eriksen EF (1986) Normal and pathological remodeling of
human trabecular bone: three dimensional reconstruction of
the remodeling sequence in normals and in metabolic bone
disease. Endocr Rev 7:379–408
3. Coindre JM, David JP, Riviere L, Goussot JF, Roger P, de
Mascarel A, Meunier PJ (1986) Bone loss in hypothyroidism
with hormone replacement: a histomorphometric study. Arch
Intern Med 146:48–53
4. Krolner B, Jorgensen JV, Nielsen SP (1983) Spinal bone min-
eral content in myxoedema and thyrotoxicosis: eﬀects of thy-
roid hormone(s) and antithyroid treatment. Clin Endocrinol
(Oxf) 18:439–446
5. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT
(1988) Long-term L-thyroxine therapy is associated with
decreased hip bone density in premenopausal women. JAMA
259:3137–3141
6. Ribot C, Tremollieres F, Pouilles JM, Louvet JP (1990) Bone
mineral density and thyroid hormone therapy. Clin Endocrinol
(Oxf) 33:143–153
7. Greenspan SL, Greenspan FS, Resnick NM, Block JE, Fried-
lander AL, Genant HK (1991) Skeletal integrity in premeno-
pausal and postmenopausal women receiving long-term
L-thyroxine therapy. Am J Med 91:5–14
8. Kung AW, Pun KK (1991) Bone mineral density in premeno-
pausal women receiving long-term physiological doses of
levothyroxine. JAMA 265:2688–2691
9. Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F,
Ruiz de Almodovar M, Jodar Gimeno E (1993) Bone mass in
females with diﬀerent thyroid disorders: inﬂuence of meno-
pausal status. Bone Miner 21:1–8
10. Garton M, Reid DM, Loveridge N, Robins S, Murchison L,
Beckett G, Reid D (1994) Bone mineral density and metabolism
in premenopausal women taking L-thyroxine replacement
therapy. Clin Endocrinol (Oxf) 41:747–755
11. Hanna FW, Pettit RJ, Ammari F, Evans WD, Sandeman D,
Lazarus JH (1998) Eﬀect of replacement doses of thyroxine on
bone mineral density. Clin Endocrinol (Oxf) 48:229–234
12. Grant DJ, McMurdo ME, Mole PA, Paterson CR, Davies RR
(1993) Suppressed TSH levels secondary to thyroxine replace-
ment therapy are not associated with osteoporosis. Clin
Endocrinol (Oxf) 39:529–533
13. Duncan WE, Chang A, Solomon B, Wartofsky L (1994)
Inﬂuence of clinical characteristics and parameters associated
with thyroid hormone therapy on the bone mineral density of
women treated with thyroid hormone. Thyroid 4:183–190
14. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J,
Sheppard M (1994) Bone mineral density in thyroxine treated
females with or without a previous history of thyrotoxicosis.
Clin Endocrinol (Oxf) 41:425–432
15. Schneider DL, Barrett-Connor EL, Morton DJ (1994) Thyroid
hormone use and bone mineral density in elderly women: eﬀects
of estrogen. JAMA 271:1245–1249
16. Hawkins F, Rigopoulou D, Papapietro K, Lopez MB (1994)
Spinal bone mass after long-term treatment with L-thyroxine in
postmenopausal women with thyroid cancer and chronic lym-
phocytic thyroiditis. Calcif Tissue Int 54:16–19
17. Cooper DS (2001) Clinical practice: subclinical hypothyroid-
ism. N Engl J Med 345:260–265
18. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA,
Lindstedt G (1988) A double-blind cross-over 12-month study
of L-thyroxine treatment of women with ‘subclinical’ hypo-
thyroidism. Clin Endocrinol (Oxf) 29:63–75
19. Ross DS (1993) Bone density is not reduced during the short-
term administration of levothyroxine to postmenopausal
women with subclinical hypothyroidism: a randomized,
prospective study. Am J Med 95:385–388
20. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W,
Cook D, Harper S, Griﬃth L, Carbotte R (1996) Does treat-
ment with L-thyroxine inﬂuence health status in middle-aged
and older adults with subclinical hypothyroidism? J Gen Intern
Med 11:744–749
215
21. Pines A, Dotan I, Tabori U, Villa Y, Mijatovic V, Levo Y,
Ayalon D (1999) L-thyroxine prevents the bone-conserving
eﬀect of HRT in postmenopausal women with subclinical
hypothyroidism. Gynecol Endocrinol 13:196–201
22. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez
AR, Drewe J, Huber P, Herzog R, Muller B (2001) TSH-con-
trolled L-thyroxine therapy reduces cholesterol levels and
clinical symptoms in subclinical hypothyroidism: a double
blind, placebo-controlled trial (Basel Thyroid Study). J Clin
Endocrinol Metab 86:4860–4866
23. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully
automated serum assay for C-terminal cross-linking telopeptide
of type I collagen in osteoporosis. Clin Chem 47:694–702
24. Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK
(1995) Accurate assessment of precision errors: how to measure
the reproducibility of bone densitometry techniques. Osteopo-
ros Int 5:262–270
25. Ross DS (1991) Monitoring L-thyroxine therapy: lessons from
the eﬀects of L-thyroxine on bone density. Am J Med 91:1–4
26. Bergmann P, Dediste A, Demeester-Mirkine N, Deconinck I,
Corvilain J (1989) Serum bone Gla protein (BGP) in primary
hypothyroidism before and during treatment with thyroid
hormones. Horm Metab Res 21:47–48
27. Gam AN, Jensen GF, Hasselstrom K, Olsen M, Nielsen KS
(1991) Eﬀect of thyroxine therapy on bone metabolism in
substituted hypothyroid patients with normal or suppressed
levels of TSH. J Endocrinol Invest 14:451–455
28. Campbell J, Day P, Diamond T (1996) Fine adjustments in
thyroxine replacement and its eﬀect on bone metabolism.
Thyroid 6:75–78
29. Woitge HW, Seibel MJ, Ziegler R (1996) Comparison of total
and bone-speciﬁc alkaline phosphatase in patients with non-
skeletal disorder or metabolic bone diseases. Clin Chem
42:1796–1804
30. Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine
treatment and occurrence of fracture of the hip. Arch Intern
Med 162:338–343
216
